Clinical Trials Logo

Filter by:
NCT ID: NCT06329622 Not yet recruiting - Clinical trials for Chronic Kidney Disease

Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

The investigators hypothesize that Ketosteril can improve sarcopenia in patients with renal disease without increasing the burden on the kidneys and causing deterioration of renal function. Therefore, this study intends to take patients with CKD stage 3-4 and sarcopenia as the research object, give Ketosteril intervention or not to patients on the base of low-protein diet, and clarify the clinical benefits of Ketosteril prescription for improving sarcopenia in patients with CKD.

NCT ID: NCT06329206 Recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors

Start date: March 20, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).

NCT ID: NCT06329167 Recruiting - Clinical trials for Lower Extremity Lymphedema

Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery

Start date: March 25, 2024
Phase: Phase 4
Study type: Interventional

This clinical trial is designed to learn more about treating patients with lower limb lymphoedema following gynaecological surgery. The main question to be answered is To evaluate the efficacy of Daphnetin capsule in the treatment of patients with lower limb lymphedema following gynaecological malignancy surgery. Participants will take Daphnetin capsule 150mg tid (3 capsules/time, 3 times daily) orally at the same time as gradient compression stocking treatment. Researchers will compare 150mg Forte tablets (2 capsules/time, 2 times daily) and gradient compression stockings to see if Daphnetin capsule can be used to treat patients with lower extremity lymphedema following gynaecological malignancy surgery.

NCT ID: NCT06329154 Recruiting - Clinical trials for Rotator Cuff Injuries

Clinical Study On Extracorporeal Shock Wave Therapy For Rotator Cuff Injuries

Start date: February 27, 2024
Phase: N/A
Study type: Interventional

This clinical trial aims to learn about the effect of extracorporeal shock wave therapy on rotator cuff injuries. The main question it aims to answer is the efficacy of extracorporeal shock wave therapy on the improvement of pain, shoulder function, and quality of life in patients with rotator cuff injuries. The experimental group of patients received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group only received conventional rehabilitation therapy. Compare the two groups to explore the therapeutic effect of extracorporeal shock wave therapy on rotator cuff injuries.

NCT ID: NCT06329076 Recruiting - Healthy Clinical Trials

Losartan Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

The main aim of the present study is to investigate the effects of orally administered losartan on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

NCT ID: NCT06329063 Recruiting - Healthy Clinical Trials

Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

NCT ID: NCT06329050 Recruiting - Healthy Clinical Trials

The Effects of Losartan on Attention Control: An Eye-tracking Study

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

The main aim of the present study is to investigate the effects of orally administered Losartan on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

NCT ID: NCT06329037 Recruiting - Healthy Clinical Trials

The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

NCT ID: NCT06328764 Enrolling by invitation - Beta-Thalassemia Clinical Trials

CS-101 in Patients With β-thalassemia

Start date: March 19, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.

NCT ID: NCT06328517 Recruiting - Cirrhosis Clinical Trials

The Influence of Nutritional Factors on the Prognosis of Liver Cirrhosis Patients and the Exploration of Predictive Models

Start date: November 1, 2023
Phase:
Study type: Observational [Patient Registry]

Cirrhosis is a progressive developing liver disease transforming normal hepatocytes into scar tissue with loss of function.The prevalence of cirrhosis has approximately tripled over the past two decades. With the increasing incidence of chronic liver disease, about 2 million people died from cirrhosis worldwide. Currently, D'Amico stage classification and Child-Pugh and Model for End-Stage Liver Disease (MELD) scores constitute the best tools to predict mortality in patients with Cirrhosis; however, one of their main limitations is the lack of evaluation of the nutritional and functional status. Patients with End-Stage Liver Disease (ESLD) have reduced nutritional intake, hypermetabolism, increased energy expenditure, impaired fasting adaptability, decreased hepatic glycogen reserves, and increased consumption of protein as the main energy donor that often lead to malnutrition, therefore, malnutrition is one of the most common complications in patients with Cirrhosis, is closely related to the increase in morbidity and mortality. Moreover, malnutrition is closely related to the high incidence of infection, ascites, hepatic encephalopathy, and hepatorenal syndrome, and is an independent risk factor affecting the survival rate of patients with End-Stage Liver Disease, including liver transplantation. Therefore, malnutrition should be treated as equally important complications such as ascites and hepatic encephalopathy, and accurate screening, evaluation and appropriate nutritional intervention measures should be taken to improve the prognosis of patients with Cirrhosis. This study aims to establish a nomogram model about nutritional factors to predict the prognosis of patients with Cirrhosis, verify and optimize the model, through the establishment of the model, to more comprehensively evaluate and predict the prognosis of patients with Cirrhosis from the perspective of nutrition, to provide sufficient basis and lay a solid foundation for further nutritional intervention and improve patient prognosis.